Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2006 by Herlev Hospital.
Recruitment status was  Recruiting
Information provided by:
Herlev Hospital Identifier:
First received: March 30, 2006
Last updated: September 20, 2006
Last verified: September 2006

March 30, 2006
September 20, 2006
November 2005
Not Provided
Clinical response
Same as current
Complete list of historical versions of study NCT00309660 on Archive Site
Endoscopic response
Same as current
Not Provided
Not Provided
Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis
Not Provided
Treatment with PPARgamma ligands have been shown to reduces intestinal inflammation in murine models of colitis. The aim of this study was to evaluate the effect of treatment with local PPARgamma ligand (rosiglitazone) in distal ulcerative colitis.The patients are treated with rosiglitazone enema, once a day, for fourteen days. Disease activity was assessed before and after treatment by endoscopical and clinical activity score.
Not Provided
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Ulcerative Colitis
Drug: Rosiglitazone
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
June 2007
Not Provided

Inclusion Criteria:

  • Distal ulcerative colitis (Mayo Clinical Score > 7)
  • Age > 18 years
  • Written consent

Exclusion Criteria:

  • Age < 18 years
  • Severe ulcerative colitis
  • Systemic treatment with steroids or azathioprin within the last 3 month
  • Known liver or kidney disease
  • Severe heart failure
  • Pregnancy or breast feeding
18 Years to 80 Years   (Adult, Senior)
Contact: Gitte Pedersen + 45 44883418
Not Provided
Not Provided
Not Provided
Not Provided
Herlev Hospital
Not Provided
Principal Investigator: Jørn Brynskov, Ass. Prof. Dept Gastroenterology C, Herlev University Hospital, 2730 Herlev, Denmark
Herlev Hospital
September 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP